GLP-1 Receptor Agonist Market
Market Insights on GLP-1 Receptor Agonist covering sales outlook, demand forecast & up-to-date key trends
GLP-1 Receptor Agonist Market By Route of Administration (Oral, Parenteral), Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), Distribution Channel (Hospitals, Clinics, Ambulatory Surgical Centres) & Region - Forecast to 2020-2030
GLP-1 Receptor Agonist Market Findings and Outlook
- The global GLP-1 Receptor Agonist Market is set to witness steady growth through 2030
- New product launches remain a key focus area for market players
- North America and Europe collectively hold more than 70% of market share, with the US holding the lion’s share
- Covid-19 to stall the market in the short term, with recovery expected in the first quarter of 2021
Let us know your requirement to get
100% FREE customization
GLP-1 Receptor Agonist Market Snapshot
Globally, nearly 463 Mn people between 20 and 70 years of age are estimated to be suffering from diabetes, as per the International Diabetes Federation in 2019.
Also, as per WHO, over 1.9 Mn adults were found to be overweight as of 2016. Obese and overweight people are at a greater risk of developing cardiovascular and gastric ailments and diabetes.
The GLP-1 receptor agonist market is influenced by an increase in the number of people categorized as obese or diagnosed as diabetics. A growth in these numbers is likely to push adoption of GLP-1 receptor agonists over the forecast period.
New Product Launches Remain Key to Growth
GLP-1 receptor agonist market players are tabling new products to gain a competitive advantage over one another. This trend is bound to drive the market in the forecast period.
For instance –
- In Jul 2020, 9 Meters Biopharma, started dosing NM-002 (long-acting GLP-1 receptor agonist), which has been designed especially for treating gastric motility by slowing down the digestive transit time
- In June 2020, Sun Pharmaceuticals announced an updation regarding its pre-clinical module. The experimental NCE (New Chemical Entity) comes across as a long-acting GLP-1R agonist for treating patients suffering from type 2 diabetes inclusive of long-acting, intermediate-acting, and short-acting therapies
- In Jun 2020, Pfizer showcased Phase I data from study assessing PF-06882961, a GLP-1R agonist in the patients contracting Type 2 Diabetes at the virtual American Diabetes Association meeting. The findings showed that this GLP-1 receptor agonist significantly reduced body weight and glucose levels in these patients
- In Jun 2020, Novo Nordisk tabled results from a real-world study – “PATHWAY” that extends support to recommendations in clinical guidelines by showcasing that initiating a GLP-1 receptor agonist does help people affected by type 2 diabetes in weight loss as well as reaching blood sugar levels.
- In Jun 2020, Novo Nordisk announced the approval of Rybelsus (oral semaglutide) (the sole oral GLP-1 R agonist in the form of a tablet) from the Japanese Ministry of Health, Labour and Welfare to treat people with type 2 diabetes
- In Apr 2020, AstraZeneca funded a clinical trial to evaluate usage of short-acting GLP-1 receptor agonists as one of the add-on treatments to insulin therapy in the type 1 diabetes.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystGLP-1 Receptor Agonist Market: R&D Activities
As per researchers at the Icahn School of Medicine, beta cells could be regenerated at much higher rates by combining DYRK1A drugs with GLP-1 receptor agonists.
The GLP-1 receptor agonists could be any of the prescribed meds like Bydureon from AstraZeneca, Trulicity from Eli Lilly, Rybelsus, Ozempic, and Victoria from Novo Nordisk.
“Diabetes Care”, published study results stating that treatment with lixisenatide GLP-1 receptor agonist significantly slows gastric emptying and reduces postprandial glycaemia. In May 2017, “Diabetes, Obesity and Metabolism” published that the ones suffering from type 2 diabetes witnessed lower frequency of gastrointestinal events with a weekly dose of exenatide (a GLP-1 receptor agonist).
“The Lancet Diabetes & Endocrinology”, in Jan 2020, published that GLP-1 receptor agonists could be considered while going for future stroke prevention guidelines for those suffering from diabetes.
Also, in Sep 2019, researchers at the 55th Annual Meeting of the European Association for the Study of Diabetes, reported that a new GLP-1 receptor agonist named “PEX168” showed positive results with respect to treatment of those suffering from type 2 diabetes
Covid-19 Impact on GLP-1 Receptor Agonist Market
The outbreak of Covid-19 has reduced the frequency of research and approvals for GLP-1 receptor agonists This scenario is expected to continue till the end of the year 2020. The normalcy is expected to get restored by the first quarter of the year 2021.
GLP-1 Receptor Agonist Market: Region-wise Analysis
North America held more than 70% of market share in the year 2019. This could be attributed to the ever-increasing utilization of GLP-1 Receptor Agonists along with a well-established demand-supply chain consisting of pharmaceutical and biopharmaceutical industry.
Europe is the second largest market for GLP-1 receptor agonist, and the growing obesity rates in the region are likely to boost adoption over the forecast period. According to the WHO also states that around 60 million people all across the Europe are suffering from diabetes.
Asia Pacific is expected to grow at the fastest rate in the forecast period due to the fact that more than 70% of the global diabetic population resides in India and China. Also, 40.9% of the population is found to be obese (as per ADB Institute).
GLP-1 Receptor Agonist Market: Competition Landscape
The GLP-1 receptor agonist market players are adopting diverse strategies like geographic expansion and mergers and acquisitions (M&A) for gaining a strong foothold.
For instance – Sanofi, in Jan 2020, made an announcement of acquiring Synthorx, Inc. This acquisition is likely to help the company to lay its hands on genetic alphabet platform technology.
Research collaborations between the players for developing new products have also been moving towards market substantiation.
For instance – Boehringer Ingelheim and Eli Lilly and Company, in Dec 2018, collaborated with DCRI (Duke Clinical Research Institute) to develop GLP-1 Receptor Agonist for addressing cardiovascular ailments and diabetes.
In addition to Eli Lily and Company, and Sanofi, key players in the GLP-1 receptor agonist market include Novo Nordisk and AstraZeneca.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
GLP-1 Receptor Agonist Market: The Way Forward
The GLP-1 Receptor Agonist Market is expected to be going strong, with FMI’s analysis predicting steady growth between 2020 and 2030. Research and innovative approaches are expected to drive the market in the near future.
The key market players need to look upon reaching out to wider geographies through inorganic expansion, so as to cater to a larger patient-base. Innovations are already on the anvil. They, coupled with mergers, acquisitions, partnerships, joint ventures will add to the competitive landscape
Key Segment
Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Others
Route of Administration
- Parenteral
- Oral
Distribution Channel
- Hospitals
- Clinics
- Ambulatory Surgical Centres
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Frequently Asked Questions
The GLP-1 receptor agonist market is likely to secure a CAGR of 10.84% through 2032.
The GLP-1 receptor agonist market size is estimated to cross US$ 11.24 Bn by 2032.
The GLP-1 receptor agonist market is likely to record a value of US$ 4.0169 Bn in 2022.
North America is likely to lead the GLP-1 receptor agonist market.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Drug Class Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development Trends
4. Key Success Factors
4.1. GLP-1 Receptor Agonist Use Cases
4.2. Regulatory Landscape
4.3. Pipeline Assessment
4.4. Key Promotional Strategies, By Manufacturers
5. Global GLP-1 Receptor Agonist Market Demand (Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030
5.1. Historical Market Value (US$ Mn) Analysis, 2015-2019
5.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Background
6.1. Macro-Economic Factors
6.1.1. Global GDP Growth Outlook
6.1.2. Per Capita Healthcare Expenditure Outlook
6.2. Forecast Factors - Relevance & Impact
6.2.1. Technology Advancements and Adoptions
6.2.2. New Product Approvals and Launches
6.2.3. Rising R & D Funding
6.2.4. Increasing Incidence and Prevalence of Chronic Diseases
6.2.5. Regulatory Policies
6.3. Market Dynamics
6.3.1. Drivers
6.3.2. Restraints
6.3.3. Opportunity Analysis
6.4. COVID19 Crisis Analysis
6.4.1. Current COVID19 Statistics and Probable Future Impact
6.4.2. Current GDP Projection and Probable Impact
6.4.3. Current Economic Projection as compared to 2008 Economic analysis
6.4.4. COVID19 and Impact Analysis
6.4.4.1. Revenue By Drug Class
6.4.4.2. Revenue By Route of Administration
6.4.4.3. Revenue By Distribution Channel
6.4.4.4. Revenue By Country
6.4.5. 2020 Market Scenario
6.4.6. Quarter by Quarter Forecast
6.4.7. Projected recovery Quarter
6.4.8. Recovery Scenario – Short term, Midterm and Long Term Impact
7. Global GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Class
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015–2019
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2020-2030
7.3.1. Exenatide
7.3.2. Liraglutide
7.3.3. Dulaglutide
7.3.4. Lixisenatide
7.3.5. Others
7.4. Market Attractiveness Analysis By Drug Class
8. Global GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030, by Route of Administration
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2015–2019
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2020-2030
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis by Route of Administration
9. Global GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015–2019
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020-2030
9.3.1. Institutional Sales
9.3.1.1. Hospitals
9.3.1.2. Clinics
9.3.1.3. Ambulatory Surgical Centers
9.3.2. Retail Sales
9.3.2.1. Hospital Pharmacy
9.3.2.2. Retail Pharmacy
9.3.3. Online Sales
9.4. Market Attractiveness Analysis By Distribution Channel
10. Global GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030, by Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2015–2019
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2020-2030
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Drug Class
11.4.3. By Route of Administration
11.4.4. By Distribution Channel
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
12. Latin America GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Drug Class
12.3.3. Route of Administration
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug Class
12.4.3. By Route of Administration
12.4.4. By Distribution Channel
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. Europe GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Class
13.4.3. By Route of Administration
13.4.4. By Distribution Channel
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. South Asia GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Thailand
14.3.1.3. Indonesia
14.3.1.4. Malaysia
14.3.1.5. Rest of South Asia
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Class
14.4.3. By Route of Administration
14.4.4. By Distribution Channel
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. East Asia GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Class
15.4.3. By Route of Administration
15.4.4. By Distribution Channel
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Oceania GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Drug Class
16.3.3. By Route of Administration
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Route of Administration
16.4.4. By Distribution Channel
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
17. Middle East and Africa GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015–2019
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2020-2030
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Turkey
17.3.1.3. Northern Africa
17.3.1.4. South Africa
17.3.1.5. Rest of Middle East and Africa
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Route of Administration
17.4.4. By Distribution Channel
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
18. Key and Emerging Countries GLP-1 Receptor Agonist Market Analysis 2015-2019 and Forecast 2020-2030
18.1. Introduction
18.1.1. Market Value Proportion Analysis, By Key Countries
18.1.2. Global Vs. Country Growth Comparison
18.2. U.S. GLP-1 Receptor Agonist Market Analysis
18.2.1. By Drug Class
18.2.2. Route of Administration
18.2.3. By Distribution Channel
18.3. Canada GLP-1 Receptor Agonist Market Analysis
18.3.1. By Drug Class
18.3.2. Route of Administration
18.3.3. By Distribution Channel
18.4. Mexico GLP-1 Receptor Agonist Market Analysis
18.4.1. By Drug Class
18.4.2. Route of Administration
18.4.3. By Distribution Channel
18.5. Brazil GLP-1 Receptor Agonist Market Analysis
18.5.1. By Drug Class
18.5.2. Route of Administration
18.5.3. By Distribution Channel
18.6. U.K. GLP-1 Receptor Agonist Market Analysis
18.6.1. By Drug Class
18.6.2. Route of Administration
18.6.3. By Distribution Channel
18.7. Germany GLP-1 Receptor Agonist Market Analysis
18.7.1. By Drug Class
18.7.2. Route of Administration
18.7.3. By Distribution Channel
18.8. France GLP-1 Receptor Agonist Market Analysis
18.8.1. By Drug Class
18.8.2. Route of Administration
18.8.3. By Distribution Channel
18.9. Italy GLP-1 Receptor Agonist Market Analysis
18.9.1. By Drug Class
18.9.2. Route of Administration
18.9.3. By Distribution Channel
18.10. Spain GLP-1 Receptor Agonist Market Analysis
18.10.1. By Drug Class
18.10.2. Route of Administration
18.10.3. By Distribution Channel
18.11. BENELUX GLP-1 Receptor Agonist Market Analysis
18.11.1. By Drug Class
18.11.2. Route of Administration
18.11.3. By Distribution Channel
18.12. Russia GLP-1 Receptor Agonist Market Analysis
18.12.1. By Drug Class
18.12.2. Route of Administration
18.12.3. By Distribution Channel
18.13. China GLP-1 Receptor Agonist Market Analysis
18.13.1. By Drug Class
18.13.2. Route of Administration
18.13.3. By Distribution Channel
18.14. Japan GLP-1 Receptor Agonist Market Analysis
18.14.1. By Drug Class
18.14.2. Route of Administration
18.14.3. By Distribution Channel
18.15. South Korea GLP-1 Receptor Agonist Market Analysis
18.15.1. By Drug Class
18.15.2. Route of Administration
18.15.3. By Distribution Channel
18.16. India GLP-1 Receptor Agonist Market Analysis
18.16.1. By Drug Class
18.16.2. Route of Administration
18.16.3. By Distribution Channel
18.17. Australia GLP-1 Receptor Agonist Market Analysis
18.17.1. By Drug Class
18.17.2. Route of Administration
18.17.3. By Distribution Channel
18.18. New Zealand GLP-1 Receptor Agonist Market Analysis
18.18.1. By Drug Class
18.18.2. Route of Administration
18.18.3. By Distribution Channel
18.19. GCC Countries GLP-1 Receptor Agonist Market Analysis
18.19.1. By Drug Class
18.19.2. Route of Administration
18.19.3. By Distribution Channel
18.20. Turkey GLP-1 Receptor Agonist Market Analysis
18.20.1. By Drug Class
18.20.2. Route of Administration
18.20.3. By Distribution Channel
18.21. South Africa GLP-1 Receptor Agonist Market Analysis
18.21.1. By Drug Class
18.21.2. Route of Administration
18.21.3. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Company Share Analysis
19.4. Market Presence Analysis
19.4.1. By Regional footprint of Players
19.4.2. Channel Foot Print by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive (Tentative List)
20.3.1. Eli Lilly and Company
20.3.1.1. Overview
20.3.1.2. Service Portfolio
20.3.1.3. Profitability by Market Segments (Service/Channel/Region)
20.3.1.4. Sales Footprint
20.3.1.5. Strategy Overview
20.3.1.5.1. Marketing Strategy
20.3.1.5.2. Service Strategy
20.3.1.5.3. Channel Strategy
20.3.2. Sanofi
20.3.2.1. Overview
20.3.2.2. Service Portfolio
20.3.2.3. Profitability by Market Segments (Service/Channel/Region)
20.3.2.4. Sales Footprint
20.3.2.5. Strategy Overview
20.3.2.5.1. Marketing Strategy
20.3.2.5.2. Service Strategy
20.3.2.5.3. Channel Strategy
20.3.3. Novo Nordisk A/S
20.3.3.1. Overview
20.3.3.2. Service Portfolio
20.3.3.3. Profitability by Market Segments (Service/Channel/Region)
20.3.3.4. Sales Footprint
20.3.3.5. Strategy Overview
20.3.3.5.1. Marketing Strategy
20.3.3.5.2. Service Strategy
20.3.3.5.3. Channel Strategy
20.3.4. AstraZeneca
20.3.4.1. Overview
20.3.4.2. Service Portfolio
20.3.4.3. Profitability by Market Segments (Service/Channel/Region)
20.3.4.4. Sales Footprint
20.3.4.5. Strategy Overview
20.3.4.5.1. Marketing Strategy
20.3.4.5.2. Service Strategy
20.3.4.5.3. Channel Strategy
20.3.5. Boehringer Ingelheim
20.3.5.1. Overview
20.3.5.2. Service Portfolio
20.3.5.3. Profitability by Market Segments (Service/Channel/Region)
20.3.5.4. Sales Footprint
20.3.5.5. Strategy Overview
20.3.5.5.1. Marketing Strategy
20.3.5.5.2. Service Strategy
20.3.5.5.3. Channel Strategy
20.3.6. Zealand Pharma A/S
20.3.6.1. Overview
20.3.6.2. Service Portfolio
20.3.6.3. Profitability by Market Segments (Service/Channel/Region)
20.3.6.4. Sales Footprint
20.3.6.5. Strategy Overview
20.3.6.5.1. Marketing Strategy
20.3.6.5.2. Service Strategy
20.3.6.5.3. Channel Strategy
20.3.7. HanmiPharm.Co., Ltd
20.3.7.1. Overview
20.3.7.2. Service Portfolio
20.3.7.3. Profitability by Market Segments (Service/Channel/Region)
20.3.7.4. Sales Footprint
20.3.7.5. Strategy Overview
20.3.7.5.1. Marketing Strategy
20.3.7.5.2. Service Strategy
20.3.7.5.3. Channel Strategy
20.3.8. GlaxoSmithKline plc.
20.3.8.1. Overview
20.3.8.2. Service Portfolio
20.3.8.3. Profitability by Market Segments (Service/Channel/Region)
20.3.8.4. Sales Footprint
20.3.8.5. Strategy Overview
20.3.8.5.1. Marketing Strategy
20.3.8.5.2. Service Strategy
20.3.8.5.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global GLP-1 Receptor Market Analysis 2015-2019 and Forecast 2020–2030, By Drug Class
Table 02: Global GLP-1 Receptor Market Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration
Table 03: Global GLP-1 Receptor Market Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel
Table 04: Global GLP-1 Receptor Market Analysis 2015-2019 and Forecast 2020–2030, By Region
Table 05: North America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country
Table 06: North America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class
Table 07: North America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration
Table 08: North America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel
Table 09: Latin America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country
Table 10: Latin America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class
Table 11: Latin America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration
Table 12: Latin America GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel
Table 13: Europe GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country
Table 14: Europe GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class
Table 15: Europe GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration
Table 16: Europe GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel
Table 17: South Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country
Table 18: South Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class
Table 19: South Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration
Table 20: South Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel
Table 21: East Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country
Table 22: East Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class
Table 23: East Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration
Table 24: East Asia GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel
Table 25: Oceania GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country
Table 26: Oceania GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class
Table 27: Oceania GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration
Table 28: Oceania GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel
Table 29: Middle East and Africa GLP-1 Receptor Market Value (US$ Mn) Analysis 2015–2019 and Forecast 2020–2030, By Country
Table 30: Middle East and Africa GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Drug Class
Table 31: Middle East and Africa GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Route of Administration
Table 32: Middle East and Africa GLP-1 Receptor Market Value (US$ Mn) Analysis 2015-2019 and Forecast 2020–2030, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global GLP-1 Receptor Market Value Analysis, 2015–2019
Figure 02: Global GLP-1 Receptor Market Forecast & Y-o-Y Growth, 2020–2030
Figure 03: Global GLP-1 Receptor Market Absolute $ Opportunity (US$ Mn) Analysis, 2019–2030
Figure 04: Global GLP-1 Receptor Market Y-o-Y Growth (%) Analysis, 2019–2030
Figure 05: Global GLP-1 Receptor Market Value Share (%) Analysis 2020 & 2030, By Drug Class
Figure 06: Global GLP-1 Receptor Market Y-o-Y Growth (%) Analysis 2019-2030, By Drug Class
Figure 07: Global GLP-1 Receptor Market Attractiveness Analysis 2020–2030, By Drug Class
Figure 08: Global GLP-1 Receptor Market Value Share (%) Analysis 2020 & 2030, By Route of Administration
Figure 09: Global GLP-1 Receptor Market Y-o-Y Growth (%) Analysis 2019-2030, By Route of Administration
Figure 10: Global GLP-1 Receptor Market Attractiveness Analysis 2020–2030, By Route of Administration
Figure 11: Global GLP-1 Receptor Market Value Share (%) Analysis 2020 & 2030, By Distribution Channel
Figure 12: Global GLP-1 Receptor Market Y-o-Y Growth (%) Analysis 2019-2030, By Distribution Channel
Figure 13: Global GLP-1 Receptor Market Attractiveness Analysis 2020–2030, By Distribution Channel
Figure 14: Global GLP-1 Receptor Market Value Share (%) Analysis 2020 & 2030, By Region
Figure 15: Global GLP-1 Receptor Market Y-o-Y Growth (%) Analysis 2019-2030, By Region
Figure 16: Global GLP-1 Receptor Market Attractiveness Analysis 2020–2030, By Region
Figure 17: North America GLP-1 Receptor Market Value Analysis, 2015–2019
Figure 18: North America GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030
Figure 19: North America GLP-1 Receptor Market Attractiveness Analysis, By Drug Class
Figure 20: North America GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration
Figure 21: North America GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel
Figure 22: North America GLP-1 Receptor Market Attractiveness Analysis, By Country
Figure 23: Latin America GLP-1 Receptor Market Value Analysis, 2015–2019
Figure 24: Latin America GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030
Figure 25: Latin America GLP-1 Receptor Market Attractiveness Analysis, By Drug Class
Figure 26: Latin America GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration
Figure 27: Latin America GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel
Figure 28: Latin America GLP-1 Receptor Market Attractiveness Analysis, By Country
Figure 29: Europe GLP-1 Receptor Market Value Analysis, 2015–2019
Figure 30: Europe GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030
Figure 31: Europe GLP-1 Receptor Market Attractiveness Analysis, By Drug Class
Figure 32: Europe GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration
Figure 33: Europe GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel
Figure 34: Europe GLP-1 Receptor Market Attractiveness Analysis, By Country
Figure 35: South Asia GLP-1 Receptor Market Value Analysis, 2015–2019
Figure 36: South Asia GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030
Figure 37: South Asia GLP-1 Receptor Market Attractiveness Analysis, By Drug Class
Figure 38: South Asia GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration
Figure 39: South Asia GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel
Figure 40: South Asia GLP-1 Receptor Market Attractiveness Analysis, By Country
Figure 41: East Asia GLP-1 Receptor Market Value Analysis, 2015–2019
Figure 42: East Asia GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030
Figure 43: East Asia GLP-1 Receptor Market Attractiveness Analysis, By Drug Class
Figure 44: East Asia GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration
Figure 45: East Asia GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel
Figure 46: East Asia GLP-1 Receptor Market Attractiveness Analysis, By Country
Figure 47: Oceania GLP-1 Receptor Market Value Analysis, 2015–2019
Figure 48: Oceania GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030
Figure 49: Oceania GLP-1 Receptor Market Attractiveness Analysis, By Drug Class
Figure 50: Oceania GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration
Figure 51: Oceania GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel
Figure 52: Oceania GLP-1 Receptor Market Attractiveness Analysis, By Country
Figure 53: Middle East and Africa GLP-1 Receptor Market Value Analysis, 2015–2019
Figure 54: Middle East and Africa GLP-1 Receptor Market Forecast & Y-o-Y growth, 2020–2030
Figure 55: Middle East and Africa GLP-1 Receptor Market Attractiveness Analysis, By Drug Class
Figure 56: Middle East and Africa GLP-1 Receptor Market Attractiveness Analysis, By Route of Administration
Figure 57: Middle East and Africa GLP-1 Receptor Market Attractiveness Analysis, By Distribution Channel
Figure 58: Middle East and Africa GLP-1 Receptor Market Attractiveness Analysis, By Country
Figure 59: U.S. GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 60: U.S. GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 61: U.S. GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 62: Canada GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 63: Canada GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 64: Canada GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 65: Mexico GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 66: Mexico GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 67: Mexico GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 68: Brazil GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 69: Brazil GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 70: Brazil GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 71: U.K. GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 72: U.K. GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 73: U.K. GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 74: Germany GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 75: Germany GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 76: Germany GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 77: France GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 78: France GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 79: France GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 80: Italy GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 81: Italy GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 82: Italy GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 83: Russia GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 84: Russia GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 85: Russia GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 86: China GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 87: China GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 88: China GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 89: Japan GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 90: Japan GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 91: Japan GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 92: South Korea GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 93: South Korea GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 94: South Korea GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 95: India GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 96: India GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 97: India GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 98: Australia GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 99: Australia GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 100: Australia GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 101: New Zealand GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 102: New Zealand GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 103: New Zealand GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 104: GCC Countries GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 105: GCC Countries GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 106: GCC Countries GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 107: Turkey GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 108: Turkey GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 109: Turkey GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Figure 110: South Africa GLP-1 Receptor Market Share Analysis (%), 2020E & 2030F
Figure 111: South Africa GLP-1 Receptor Market Share Analysis (%), By Drug Class, 2020E
Figure 112: South Africa GLP-1 Receptor Market Share Analysis (%), By Route of Administration, 2020E
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
